Guggenheim Securities, the investment banking arm of Guggenheim Partners, has formed a strategic alliance with Australia’s ...

Guggenheim has initiated Metsera at buy saying that the biotech's pipeline of injectable and oral nutrient stimulated hormone ...

Guggenheim has initiated coverage of Metsera (NASDAQ:MTSR) with a buy rating, citing the company's obesity drug candidates.

Set on La Gorce Island, a Miami Beach residence listed for $88 million—dubbed Okto—spans nearly 16,000 square feet with 260 ...

Sempra (NYSE:SRE – Get Free Report) had its price target dropped by Guggenheim from $95.00 to $87.00 in a note issued to investors on Wednesday,Benzinga reports. The brokerage presently has a “buy” ...

The trial of three men accused in the theft or sale of an 18-carat gold toilet that was a pricey piece of satirical art is ...

Guggenheim reiterated their sell rating on shares of Tesla (NASDAQ:TSLA – Free Report) in a research note issued to investors on Tuesday,Benzinga reports. A number of other analysts have also recently ...

Guggenheim initiated coverage of Sportradar (SRAD) with a Buy rating and $27 price target Discover the Best Stocks and Maximize Your Portfolio: ...

The performance artist Marina Abramovic celebrated the announcement of a new cultural center in a private home designed by ...

As previously reported, Guggenheim analyst Michael Schmidt initiated coverage of Compass Therapeutics (CMPX) with a Buy rating and $12 price ...

Be the first to know about the biggest and best luxury home sales and listings by signing up for our Mansion Deals email ...

Guggenheim analyst sees significant upside in Metsera stock to $56. MTSR is working on both injectable and oral weight-loss ...